Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CalciMedica, Inc. stock logo
CALC
CalciMedica
$1.83
+2.2%
$1.72
$1.43
$5.97
$25.57M1.2645,403 shs17,338 shs
Generation Bio Co. stock logo
GBIO
Generation Bio
$0.42
+5.8%
$0.39
$0.32
$3.65
$28.29M2.66327,946 shs441,770 shs
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$0.00
$1.50
$19.37
$7.07M2.899,592 shs4,300 shs
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
$0.88
$0.88
$0.62
$1.47
$26.53M1.221,000 shsN/A
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CalciMedica, Inc. stock logo
CALC
CalciMedica
+2.87%+9.15%-10.50%-13.53%-64.97%
Generation Bio Co. stock logo
GBIO
Generation Bio
-8.72%+3.51%+13.39%-21.64%-87.79%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CalciMedica, Inc. stock logo
CALC
CalciMedica
1.5705 of 5 stars
3.53.00.00.00.01.70.0
Generation Bio Co. stock logo
GBIO
Generation Bio
2.9089 of 5 stars
3.53.00.00.00.63.31.3
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CalciMedica, Inc. stock logo
CALC
CalciMedica
3.00
Buy$18.00883.61% Upside
Generation Bio Co. stock logo
GBIO
Generation Bio
3.00
Buy$7.331,641.88% Upside
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
0.00
N/AN/AN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest INNVD, GBIO, PXSLY, and CALC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
CalciMedica, Inc. stock logo
CALC
CalciMedica
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
5/8/2025
Generation Bio Co. stock logo
GBIO
Generation Bio
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
4/10/2025
Generation Bio Co. stock logo
GBIO
Generation Bio
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
4/1/2025
CalciMedica, Inc. stock logo
CALC
CalciMedica
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
3/17/2025
Generation Bio Co. stock logo
GBIO
Generation Bio
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
3/14/2025
Generation Bio Co. stock logo
GBIO
Generation Bio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$5.00
3/14/2025
Generation Bio Co. stock logo
GBIO
Generation Bio
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
(Data available from 6/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CalciMedica, Inc. stock logo
CALC
CalciMedica
N/AN/AN/AN/A$1.42 per shareN/A
Generation Bio Co. stock logo
GBIO
Generation Bio
$24.56M1.15N/AN/A$3.07 per share0.14
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$23.99M0.00N/AN/A$0.05 per share0.00
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
$8.75M3.03N/AN/A$0.04 per share22.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CalciMedica, Inc. stock logo
CALC
CalciMedica
-$34.36M-$1.56N/AN/AN/AN/A-164.24%-103.53%8/11/2025 (Estimated)
Generation Bio Co. stock logo
GBIO
Generation Bio
-$126.61M-$1.08N/AN/AN/A-782.86%-104.85%-49.54%8/6/2025 (Estimated)
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
-$8.28M-$4.16N/A0.00N/A-34.51%-682.54%-78.57%N/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
-$9.36MN/A0.00N/AN/AN/AN/AN/A

Latest INNVD, GBIO, PXSLY, and CALC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
CalciMedica, Inc. stock logo
CALC
CalciMedica
-$0.43-$0.36+$0.07-$0.36N/AN/A
5/7/2025Q1 2025
Generation Bio Co. stock logo
GBIO
Generation Bio
-$0.25-$0.22+$0.03-$0.22$1.70 million$8.72 million
3/27/2025Q4 2024
CalciMedica, Inc. stock logo
CALC
CalciMedica
-$0.48-$0.34+$0.14-$0.34N/AN/A
3/19/2025Q4 2024
Generation Bio Co. stock logo
GBIO
Generation Bio
-$0.31-$0.32-$0.01-$0.32$2.92 million$4.19 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CalciMedica, Inc. stock logo
CALC
CalciMedica
N/AN/AN/AN/AN/A
Generation Bio Co. stock logo
GBIO
Generation Bio
N/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CalciMedica, Inc. stock logo
CALC
CalciMedica
N/A
4.15
4.15
Generation Bio Co. stock logo
GBIO
Generation Bio
N/A
6.34
6.34
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/A
0.68
0.36
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
2.82
3.31
2.92

Institutional Ownership

CompanyInstitutional Ownership
CalciMedica, Inc. stock logo
CALC
CalciMedica
N/A
Generation Bio Co. stock logo
GBIO
Generation Bio
95.22%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
10.38%
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/A

Insider Ownership

CompanyInsider Ownership
CalciMedica, Inc. stock logo
CALC
CalciMedica
41.55%
Generation Bio Co. stock logo
GBIO
Generation Bio
21.80%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
16.43%
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
CalciMedica, Inc. stock logo
CALC
CalciMedica
3013.97 million7.88 millionNo Data
Generation Bio Co. stock logo
GBIO
Generation Bio
15067.04 million52.70 millionOptionable
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
122.36 millionN/ANot Optionable
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
6930.15 millionN/ANot Optionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

CalciMedica stock logo

CalciMedica NASDAQ:CALC

$1.83 +0.04 (+2.23%)
As of 01:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Generation Bio stock logo

Generation Bio NASDAQ:GBIO

$0.42 +0.02 (+5.78%)
As of 01:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Innovus Pharmaceuticals stock logo

Innovus Pharmaceuticals OTCMKTS:INNVD

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Pharmaxis stock logo

Pharmaxis OTCMKTS:PXSLY

$0.88 0.00 (0.00%)
As of 06/8/2021

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.